-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CSL-311 in Allergic Asthma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CSL-311 in Allergic Asthma Drug Details: CSL-311 is under development for the treatment of allergic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Age Related Macular Degeneration
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Age Related Macular Degeneration Drug Details: Iptacopan hydrochloride (Fabhalta) is a factor B...
-
Product Insights
NewSickle Cell Disease – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease – Drugs In Development, 2024 report and make more profitable business decisions. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewSystemic Sclerosis (Scleroderma) – Drugs In Development, 2024
Empower your strategies with our Systemic Sclerosis (Scleroderma) – Drugs In Development, 2024 report and make more profitable business decisions. Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pain, joint pain and swelling, ulcers occurring on the fingertips, bloating, and diarrhea or constipation. Treatment includes antibiotics, pain relievers, and immunosuppressants. The Systemic Sclerosis (Scleroderma) drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
NewDermatological Disorders – Drugs In Development, 2024
Empower your strategies with our Dermatological Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Dermatological disorders are diseases or conditions that affect the skin, hair, or nails. They can have various causes, symptoms, and treatments. Some of the most common dermatological disorders are acne, eczema, psoriasis, rosacea, and warts. Dermatologists are doctors who specialize in diagnosing and treating these disorders. Dermatological disorders can affect the appearance, function, and quality of life of the patients. Some of...
-
Product Insights
NewHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drugs In Development, 2024
Empower your strategies with our Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing,and difficulty breathing. Treatment includes medications such as epinephrine, antihistamines, and corticosteroids. The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH]...
-
Product Insights
NewAcute Coronary Syndrome – Drugs In Development, 2024
Empower your strategies with our Acute Coronary Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Acute coronary syndrome (ACS) encompasses ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina, constituting a subset of coronary heart disease (CHD) responsible for a third of deaths in individuals over 35. Unlike some asymptomatic forms of CHD, ACS is always symptomatic. Diagnosis begins with an ECG, crucial for distinguishing between STEMI, NSTEMI, and unstable angina. Initial ACS...
-
Product Insights
NewBronchiectasis – Drugs In Development, 2024
Empower your strategies with our Bronchiectasis – Drugs In Development, 2024 report and make more profitable business decisions. Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. This damage allows bacteria and mucus to build up in the lungs. Bronchiectasis is divided into two categories: cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss, and fever. Causes of bronchiectasis include inhaling a foreign object, cystic...
-
Product Insights
NewDermatomyositis – Drugs In Development, 2024
Empower your strategies with our Dermatomyositis – Drugs In Development, 2024 report and make more profitable business decisions. Dermatomyositis is a rare inflammatory disease characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids. The Dermatomyositis drugs in development market research report provide comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage...